Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Alixorexton · ALKS-2680, RDC-264177-00

Small molecule · developed by Alkermes

Phase 3 Most advanced trial

ALKS Developer

2 Registered trials

What is Alixorexton?

Alixorexton (ALKS 2680) is an oral tablet taken daily. It is being studied in narcolepsy type 1 and narcolepsy type 2.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ALKS-2680, RDC-264177-00
Drug type: Small molecule
Therapy area: Neurology
Developer: Alkermes, Inc. (ALKS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 3BRW4ARU66

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07540897	Phase 3	Narcolepsy Type 1	Recruiting	ALKS
NCT07502443	Phase 3	Narcolepsy Type 2	Recruiting	ALKS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Narcolepsy Type 1Narcolepsy Type 2

More from Alkermes

Aripiprazole Lauroxil FDA approved Samidorphan FDA approved ALKS 1140 Phase 1 ALKS 2680 Phase 2/3 ALKS 3831 Phase 3 ALKS 5461 Phase 3 ALKS 7290 Phase 2 RDN-929 Phase 1

Sources

ClinicalTrials.gov NCT07502443

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALKS page.

Follow ALKS, the company behind Alixorexton

See ALKS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALKS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z